New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Efficacy and toxicity of hyperfractionated thoracic reirradiation.
ÌÇÐÄ´«Ã½
Efficacy and toxicity of hyperfractionated thoracic reirradiation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Butler, S. S., Raclin, T., Lau, B., Raja, N., Skinner, L., Kastelowitz, N., Chin, A. L., Diehn, M., Loo, B. W., Vitzthum, L. K. 2025: 111001Abstract
Hyperfractionated reirradiation (re-RT) has been shown to mitigate late toxicity for some cancers, but data on safety and efficacy for thoracic tumors are limited.We evaluated a cohort of 28 consecutive cases among 25 patients treated with re-RT to either primary or metastatic thoracic tumors, using 60?Gy in 50 fractions delivered twice daily. Incidence rates of toxicity, local recurrence (LR), and any disease progression were evaluated using competing risk analysis. Cumulative dose to organs at risk (OARs) was calculated (EQD2 [alpha/beta?=?3]), correlated with toxicity outcomes, and compared to published constraints for re-RT.There was direct overlap of 100?% isodose lines between treatment courses in 90.5?% of cases. Most patients had tumors abutting the proximal bronchial tree (PBT, 89?%). The median re-RT PTV volume was 67?cm3. The overall rate of?=G2 toxicity was 46?% and the rate of?=?G3 toxicity was 15?%. The rate of local recurrence and overall survival at 12?months was 33?% and 80?%, respectively. The lung volume receiving a cumulative dose of 20?Gy was kept under 40?% (V20 Gy?
View details for
View details for